INVESTIGATOR-INITIATED STUDIES (IIS) AND EXTERNAL COLLABORATIVE RESEARCH (ECR) PROJECTS SUPPORTED BY BOEHRINGER INGELHEIM

Boehringer Ingelheim provides support to academic and clinical scientists for independent (IIS) or collaborative (ECR) research projects related to ILDs


25 interventional There are with 29 new studies 2020 These 66 non-interventional include **13** preclinical studies ongoing studies

Projects span IPF, SSc-ILD and a broad range of other ILDs; in 2020, several COVID-19 research studies commenced

Key studies currently in progress are outlined below


INTERVENTIONAL STUDIES


COVID-19



AUTOIMMUNE ILDs

Nintedanib clinical trials NIN-2018-023 Tolerability and safety of nintedanib in myositis-associated ILD 22 D Assayag





Studies of diagnostic, prognostic

Early detection of progressive

fibrosis in patients with ILAs

and monitoring methods


L Hariri


ECR_2020_00002025

20

NON-INTERVENTIONAL STUDIES

IPF





HATT

300

3240

Registry studies

E Volkmann

M Kreuter

The gut microbiome as a

Studies of prognostic indicators

screening tool for ILD in SSc

Predictors for the development

ILD; SSc, systemic sclerosis; SSc-ILD, systemic sclerosis-associated interstitial lung disease

and progression of ILD in SSc





Studies of prognostic indicators

disease progression

characterization

L Kawano-Dourado

Hypersensitivity pneumonitis –

NIN-2020-004

THIR

150

pulmonary fibrosis; LAM, lymphangioleiomyomatosis; LUS, lung ultrasound; PF, pulmonary fibrosis; RA, rheumatoid arthritis; RA-ILD, rheumatoid arthritis-associated

IIS_2020_00001917

NIN-2016-006